“Digital transformation is not about technology deployment. It’s about a new way of doing business that allows you to make jumps which were not possible before, like reducing launch time from 70 weeks to 7 weeks.” – Dr. Franziskus Kath
“Cell and gene therapy is in a winter period. We just need to hold our breath and adapt ourselves to the weather,” observed Miguel Forte, President of ISCT & CEO of Kiji Therapeutics. Miguel Forte chaired the Advanced Therapies UK
“What we’re witnessing is a fundamental shift from globalized to decentralized pharma supply chains, yet many companies are hesitant to make the bold capacity investments needed despite recognizing the risks.” – Stephan Fath, Director at Roland Berger Stephan Fath is
“Every CDMO is going to give you the Disney effect. I want to see what’s below the street. How is that organisation humming below the surface?” says John Philips, highlighting why superficial evaluations are undermining pharmaceutical outsourcing success. John Philips,
“Every minute, over 1000 patients are using a product manufactured in one of our sites,” reveals Kerstin Vieluf, Head of Sales at Recipharm. Headquartered in Stockholm, Sweden, Recipharm has over 5,900 employees across 17 sites in Europe, US, India, and
“I believe that if a quality culture is really embedded, the quality organisation starts reducing, because the more quality is embedded in the organisation, the less you need quality to help you think.” – Liesbeth Foesters Liesbeth Foesters, Vice President
Maurice van Rotterdam, Co-Founder of Netherlands-based digital marketing agency Sciential, believes many pharma suppliers and CDMOs are still missing the mark when it comes to effective digital marketing. “If I look at CDMO or pharma supplier websites, they typically have
An analysis of the CDMOs operating facilities in North America by Small Molecule, Biologics and Cell & Gene Therapy.
“Seven out of ten medicines dispensed in Europe are generic products. When we only look at price, we don’t take into consideration all the efforts European companies make on sustainability. This is an industry we must protect,” says Elisabeth Stampa,
“We can cut preclinical development from five years to 18 months. Molecules which are AI-enabled in some way seem to be doing better in Phase 1 than standard molecules.” – Dr. Eva-Maria Hempe, Head of Healthcare & Life Sciences EMEA
Stay ahead of trends and best practices
Exclusive downloads and podcasts
Get invites to special events and meetups 
Help us find the most innovative and trusted suppliers in Pharma and Biotech.
